Saturday 21 December 2024
Internal Reference Number: FOI_8197
Date Request Received: 09/10/2024 00:00:00
Date Request Replied To: 23/10/2024 00:00:00
This response was sent via: By Email
Request Summary: Breast Cancer
Request Category: Researcher
| Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide • Aromatase Inhibitor as a single agent • Atezolizumab • Capecitabine as a single agent • Carboplatin + Paclitaxel • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Parp Inhibitors (Olaparib/Talazoparib) • Pembrolizumab • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Transtuzumab deruxtecan • Trastuzumab as a single agent or in combination • Trastuzumab emtansine • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 17 • Abemaciclib + Fulvestrant <5 • Alpelisib + Fulvestrant 0 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide <5 • Aromatase Inhibitor as a single agent unable to answer- only combination treatment prescribed on Aria and usually patients will get this from their GP. • Atezolizumab 0 • Capecitabine as a single agent 6 • Carboplatin + Paclitaxel <5 • Eribulin as a single agent or in combination <5 • Everolimus + Exemestane <5 • Fulvestrant as a single agent 0 • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 28 • Palbociclib + Fulvestrant <5 • Parp Inhibitors (Olaparib/Talazoparib) <5 • Pembrolizumab <5 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 13 • Ribociclib + Fulvestrant <5 • Sacituzumab Govitecan <5 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent <5 • Transtuzumab deruxtecan 5 • Trastuzumab as a single agent or in combination 39 • Trastuzumab emtansine <5 • Any other active systemic anti-cancer therapy 23 | |
| Question Number 2: Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part. | |
| Answer To Question 2: Salisbury NHS Foundation Trust is currently hosting fewer than 5 breast cancer research studies defined by IRAS as clinical trials. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
